Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors

15 Oct 2019

Abstract excerpt

Non-small cell lung carcinoma (NSCLC) is the major cause of cancer-associated mortality. Identification of rearrangements in anaplastic lymphoma kinase (ALK) gene is an effective instrument for more effective targeted therapy of NSCLC using ALK inhibitors dramatically raising progression-free survival in the ALK-mutated group of patients. However, the tumors frequently develop resistance to ALK inhibitors. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31681574
DOI: 10.3389/fonc.2019.01026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK InhibitorsPMID 31681574Read ↗

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.Semantic proximity Read ↗

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patientsSemantic proximity Read ↗

ALK gene alterations in cancer: biological aspects and therapeutic implications.Semantic proximity Read ↗

Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse.Semantic proximity Read ↗

Preclinical Prediction of Resistance and Optimization of Sequential Therapy for ALK-positive Lung Cancer Using Next-generation ALK InhibitorsSemantic proximity Read ↗

Individualized treatment of NSCLC: from research to clinical practice.Semantic proximity Read ↗

Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice.Semantic proximity Read ↗

Optimal Treatment Strategy for Oligo-Recurrence Lung Cancer Patients With Driver MutationsSemantic proximity Read ↗

Targeting ALK: Precision Medicine Takes on Drug Resistance.Semantic proximity Read ↗

Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.Semantic proximity Read ↗

Integrated machine learning survival framework for consensus modeling in a large multicenter cohort of NSCLC resistant to aumolertinibSemantic proximity Read ↗

Integrated analysis of the clinical consequence and associated gene expression of ALK in ALK-positive human cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.